
Alkermes (ALKS) Stock Forecast & Price Target
Alkermes (ALKS) Analyst Ratings
Bulls say
Alkermes PLC is positioned for robust revenue growth through 2030, bolstered by the immediate profitability of Lumryz and the anticipated annualized sales of approximately $265-$275 million by 2025, with potential for considerable expansion in subsequent years. The company's strategic investments, particularly in alixorexton's development and ongoing growth initiatives for Aristada and Lybalvi, are expected to enhance earnings per share as it navigates patent expirations and royalty reductions. The successful acquisition of Lumryz not only strengthens Alkermes' commercial capabilities but also aligns with essential growth drivers that support both near-term revenue and long-term financial stability.
Bears say
Alkermes PLC faces a negative outlook primarily due to the projected decline in Lumryz sales beyond 2030, along with the loss of exclusivity in 2037, which is expected to contribute to a stagnating revenue growth trajectory amid increasing competition in the narcolepsy treatment space. The company's reliance on the performance of its orexin program, which is still in early-stage development, poses significant risks, particularly if the efficacy and safety are not established in larger studies. Additionally, potential erosion of its royalty business and the effects of evolving payer dynamics could pressure earnings, further reinforcing the negative perspective on the company's financial stability.
This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.
Alkermes (ALKS) Analyst Forecast & Price Prediction
Start investing in Alkermes (ALKS)
Order type
Buy in
Order amount
Est. shares
0 shares